- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05577728
Replication of the SEPRA Diabetes Trial in Healthcare Claims Data
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02120
- Brigham and Women's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Please see https://drive.google.com/drive/folders/1WD618wrywYjEaXzfLTcuK-VCcnb6b-gV for full code and algorithm definitions.
All patients will be required to have continuous enrollment during the baseline period of 180 days before initiation of semaglutide or standard of care (SGL2i, 2nd generation SU, DPP-4i and GLP-1 RA except for semaglutide inj or oral) (cohort entry).
Eligible cohort entry dates:
Market availability of semaglutide/standard of care in the US started on December 6th, 2017:
- For Optum: December 6, 2017 - June 30, 2021 (end of data availability)
Inclusion Criteria:
- Age >= 18
- Type 2 diabetes mellitus diagnosis
- Use of metformin
- At least 2 HbA1c records within the prior 280 days
- At least 1 HbA1c record >= 7% within the prior 90 days
Exclusion Criteria:
- Missing age or gender
- Use of any other anti-diabetes medications
- Any insulin use
- Pregnancy
- Multiple Endocrine Neoplasia syndrome type 2
- CKD stage 5, ESRD, dialysis, or renal transplant
- Nursing home admission
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
New use of semaglutide injection
Exposure group
|
New use of semaglutide injection dispensing claim is used as the exposure.
|
New initiation of "standard of care"
(SGL2i, 2nd generation SU, DPP-4i and GLP-1 RA except for semaglutide inj or oral) Reference group
|
New initiation of "standard of care" (SGL2i, 2nd generation SU, DPP-4i and GLP-1 RA except for semaglutide inj or oral) dispensing claim is used as the reference.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Long-term glycemic control defined as proportion of patients who will achieve an HbA1c of less than 7.0% (53.0 mmol/mol)
Time Frame: At year 1
|
Number of subjects
|
At year 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in HbA1c
Time Frame: At 1 year
|
Change in HbA1c from baseline at 365 days after drug initiation.
|
At 1 year
|
Number of hypoglycemic episodes leading to an inpatient admission or emergency room encounter.
Time Frame: At 1 year
|
At 1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Shirley Wang, PhD, ScM, Brigham and Women's Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2018P002966-DUP-SEPRA
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
Diabetes Foundation, IndiaNational Diabetes Obesity and Cholesterol FoundationRecruitingType 2 Diabetes Mellitus With ComplicationIndia
Clinical Trials on New use of semaglutide injection
-
UroSee CorporationUnknownBladder TumorUnited States
-
Sunnaas Rehabilitation HospitalMade for MovementCompleted
-
Region Örebro CountyÖrebro kommun; Kumla kommunWithdrawnUrinary Incontinence | Urinary Tract Infections | Cognition Disorders in Old Age | Incontinence-associated Dermatitis | Behavioral and Psychiatric Symptoms of DementiaSweden
-
Hospital Israelita Albert EinsteinCompletedPneumonia, Aspiration | AnesthesiaBrazil
-
Universita di VeronaCompletedPerineal Tear | Delivery; Injury, Maternal | Episiotomy WoundItaly
-
Chengdu Brilliant Pharmaceutical Co., Ltd.Not yet recruitingType 2 Diabetes Mellitus
-
Yonsei UniversityTerminatedLumbosacral Radicular PainKorea, Republic of
-
Hangzhou Jiuyuan Gene Engineering Co. Ltd.,CompletedDiabetes Mellitus, Type 2China
-
The University of Hong KongNot yet recruitingMyocardial InjuryChina
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Not yet recruitingType 2 Diabetes Mellitus